IXHL IXHL
Company Profile ↓Company Overview
IXHL (IXHL) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 616.7% CAGR over the past five years.
Recent Developments
- Jun 2025 Revenue of $86.00K (+616.7% YoY); net profit $-46.88M.
- Trailing 12 Months Year-on-year growth — revenue +616.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 616.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 616.67% |
| 1 Year: | 616.67% |
Stock Price Performance
| 1 Year: | -76.93% |
| 6 Months: | -63.46% |
| 3 Months: | -35.16% |
| 1 Month: | -16.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 616.7% over 5 years.
CONS
- Trading 86.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 74.00K | 12.00K | - | - | - | - |
| Operating Income | -3.64M | -3.65M | -4.89M | -7.98M | -7.42M | -6.25M | -5.00M | -5.00M | -6.79M | -7.00M | -4.05M |
| Net Income | -2.92M | -3.57M | -726.00K | -5.24M | -6.03M | -5.42M | -5.89M | -3.97M | -6.41M | -6.52M | -3.88M |
| Diluted EPS | 0.05 | -0.22 | -0.08 | -0.33 | -0.38 | -0.29 | -0.33 | -6.19 | -0.02 | -0.02 | -0.35 |
| R&D Expense | 1.55M | 1.64M | 2.61M | 2.64M | 3.28M | 2.90M | 1.41M | 2.73M | 1.12M | 2.28M | 321.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|
| Revenue | - | 12.00K | 86.00K |
| Operating Income | -49.67M | -30.04M | -23.79M |
| Net Income | -48.81M | -18.46M | -46.88M |
| Diluted EPS | -3.32 | -1.15 | -1.35 |
| R&D Expense | 6.31M | 12.88M | 10.75M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | - | 23.78M | 17.05M | 20.45M |
| Total Equity | 24.71M | 20.82M | 11.22M | 13.39M |
| Cash & Equivalents | - | 22.12M | 5.86M | 15.04M |
| Total Liabilities | - | 2.96M | 5.83M | 7.06M |
| Current Liabilities | - | 2.55M | 5.62M | 6.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|
| Operating Cash Flow | -10.75M | -15.85M | -12.51M |
| Investing Cash Flow | -316.00K | -277.00K | -8.00K |
| Financing Cash Flow | 8.18M | - | 21.40M |
| Capital Expenditure | -316.00K | -277.00K | -8.00K |
| Free Cash Flow | -11.06M | -16.12M | -12.52M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | -250,341.7% | -27,661.6% |
| Net Margin % | - | -153,825.0% | -54,517.4% |
| ROE % | -234.4% | -164.6% | -350.2% |
| ROCE % | -233.9% | -262.9% | -176.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IXHL
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxORTVDa0ZGMHlqaHRWUkVvWHBZQUNQaUliUXFMM3MwN3FrRXJrckVVN2FNMlg4dVZKajlmTWFPQ1VoeUlCUzJ4WlVqWkt6QmQtcGRPd2puYlVZckNNX0lDVWFKaE5kTEt3M0pySXNsRTlsd3lGNTlMcVA4MmRlZlhRVEcxWkZpTjc1RmtMc3…
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxObFByRzY1N2ZmNl9CWUNFTTIyZXplc3I0X0t1Si1JaDRPNF9OeUFqZFZ6YkxVOHRQQ1R5MGd1WFRfeTRYOEtkX0pobV93U3VSSk9VUnFvUlZ2a3RUNUxRam4tbWItSy1USndEcVNRWlhKZ0hOd1huajBoWldRSkdnSkhYc2Z2dEE?oc=5" …
IXHL Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBianU0NklEak15WmFLdTdlS1JVenVpZFBQVnFhX2FVZldJWHhGZDEwMUNRdWVLMVctRmhqamdYbzRVNUZITTFaQ1hCNXBFN1A5SlpQRV9udm93VU5wWGRFaER3Sl9nTlJ5bFoxN1RzeXEzR1h6dUg4bDN3?oc=5" target="_blank">IXH…
IXHL Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE8zMW5NUnlrSjlqLVpqckFxTXRQd1RUSjRnelBTcWRTRkpnU1g3dExGZ1ZmQmlyMzN0R0Zyb1RseXBIc1ctME44MEZmR1ExTjdRWVA4R3VxanV3dWZvVnc?oc=5" target="_blank">IXHL Should I Buy</a> <font c…
Incannex's sleep apnea drug gets U.S. patent protection to 2040 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPSW51Rll1cVdveDA2bDVCN250V0JxVkVZMjFHSlJtYnJORWlOUlRGOXdmTWdGNzFaNXhfMTNKWGFvQnBvLWZjb3gtWThWRWVpTlNYWlNYOWJtYlRPSklwX1VBcTA3S05sWU5aRGxjRlZqR2tJM0ZMal9YY3pKem16cFcyYVdhTjY1M0VVN2…
Incannex Healthcare Inc. Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance | IXHL Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQY1NnVEdfU21DOURvWXNBdFpjTWlUUmN0TkNBbDc4ZGdGMjlPQnBJZXhaMC1WXy0ydTUyRkhvS2dCOHgxQ0lfUTR5UkZMVFZvV0JUemhudUJEdEZvcXpEcXJoakx5dVBCWTJGOXJyZ3BjbGFhS09Wb2FXcVFYRWlsc2FGN2FNSzNVQ0NwaU…
IXHL — Frequently Asked Questions
What is the current share price of IXHL?
As of 2026-08-05 17:25 PDT, IXHL trades at $3.08 on NASDAQ/NYSE. Its 52-week range is $2.56 to $22.23.
What is the P/E ratio of IXHL?
IXHL trades at a trailing price-to-earnings (P/E) ratio of -2.28.
Is IXHL a good stock to buy?
This page provides a data-driven analysis of IXHL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.